IP Library Granted Patent US 8,603,817
Granted Patent B2
US 8,603,817 · App. 12/611,569 · Granted Dec 10, 2013

Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling

Inventors: Michael A. LaFlamme (Seattle, WA); Wei-Zhong Zhu (Seattle, WA)
Assignee: University of Washington
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,603,817
App. No.
12/611,569
Granted
Dec 10, 2013
Kind
B2
Abstract

The present invention is directed to methods of producing cardiomyocytes having a nodal/pacemaker phenotype and cardiomyocytes having an atrial/ventricular phenotype. Isolated populations of nodal/pacemaker and atrial/ventricular cardiomyocytes are also disclosed. Methods of treating a subject having cardiac arrhythmia and a subject in need of cardiac tissue repair using the isolated populations of nodal/pacemaker cardiomyocytes and atrial/ventricular cardiomyocytes, respectively, are also disclosed.

Claims (8)

1. A composition comprising an isolated population of nodal/pacemaker cardiomyocytes having a spontaneous firing rate of >90 bpm and a slow, biphasic action potential upstroke of <15V/s and an inhibitor of the NRG-1β/ErbB signaling pathway.

2. The composition comprising an isolated population of nodal/pacemaker cardiomyocytes of claim 1 , wherein the inhibitor of the NRG-1β/ErbB signaling pathway is an antibody or a small molecule.

3. The composition comprising an isolated population of nodal/pacemaker cardiomyocytes of claim 2 , wherein the small molecule is AG1478.

4. The composition comprising an isolated population of nodal/pacemaker cardiomyocytes of claim 2 , wherein the antibody comprises an NRG1β antibody.

5. A composition comprising an isolated population of cells comprising at least 30% nodal/pacemaker cardiomyocytes having a spontaneous firing rate of >90 bpm and a slow biphasic action potential upstroke of <15 V/s, wherein the isolated population of cells is produced by contacting human embryonic stem cell derived cardiomyocytes (hESC-CM) with an inhibitor of the NRG-1β/ErbB signaling pathway.

6. The composition comprising an isolated population of nodal/pacemaker cardiomyocytes of claim 5 , wherein the inhibitor of the NRG-1β/ErbB signaling pathway is an antibody or a small molecule.

7. The composition comprising an isolated population of nodal/pacemaker cardiomyocytes of claim 6 , wherein the small molecule is AG1478.

8. The composition comprising an isolated population of nodal/pacemaker cardiomyocytes of claim 6 , wherein the antibody comprises an NRG1β antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2010
From: LAFLAMME, MICHAEL A.; ZHU, WEI-ZHONG
To: WASHINGTON, UNIVERSITY OF
Reel/Frame 024175/0688 →
CONFIRMATORY LICENSE Recorded Dec 1, 2009
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023587/0386 →
Continuity (2)
Provisional Application 61110793 · Nov 3, 2008
Related Publication 20100183565A1 · Jul 22, 2010